Odronextamab demonstrated a 48.3% objective response rate and 31.7% complete response rate in R/R DLBCL patients post-CAR-T therapy. The median duration of response was 14.8 months, with ...

About the Odronextamab Clinical Development ProgramOdronextamab is a CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell ...

Odronextamab is approved as Ordspono in the European Union for the treatment of R/R FL or diffuse large B-cell lymphoma (DLBCL). The views and opinions expressed herein are the views and opinions ...

When my co-founder and I started Invoice Home, we wanted to build a business that could grow over time. We noted many inefficiencies while discussing our past experiences working within ...

Video content above is prompted by the following: Thanks to all of you for this rich and informative discussion. Before we conclude, I’d like to get final thoughts from each of you.

odronextamab, and itepekimab. At the same time, when forecasting the growth rates of revenue and net income of the New York-based company, I took into account, among other things, the decline in ...

driven by the expanded labels of Eylea HD and Libtayo and by the potential launches of Ordspono (odronextamab), linvoseltamab, itepekimab, pozelimab/cemdisiran, and the novel oncology combination ...

The company is advancing several promising R&D programs, including pivotal data expected for Linvoseltamab in multiple myeloma and odronextamab in follicular lymphoma. Regeneron Pharmaceuticals ...

The FDA has turned down a pair of marketing applications for Regeneron’s CD20xCD3 bispecific antibody odronextamab to treat two common forms of non-Hodgkin lymphoma (NHL). The decision throws a ...

We expect regulatory approvals for linvoseltamab in relapsed/refractory multiple myeloma, odronextamab in late-line follicular lymphoma, and the aforementioned Libtayo indication in adjuvant CSCC.

such as successful determination and prediction of RNA structure and role in disease, but also to drive forward optimized strategies to improve target selection and gain pre-clinical proof of ...

Structure-based drug design is the design and optimization of a chemical structure with the goal of identifying a compound suitable for clinical testing — a drug candidate. It is based on ...